var data={"title":"Liposomal vincristine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Liposomal vincristine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/518090?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=liposomal-vincristine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Liposomal vincristine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14793786\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Not for intrathecal use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">For IV use only - fatal if given by other routes. Death has occurred with intrathecal administration.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Do not interchange:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Vincristine (liposomal) injection has different dosage recommendations than vincristine injection. Verify drug name and dose prior to preparation and administration to avoid overdosage.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673721\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Marqibo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14793788\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimicrotubular;</li>\n      <li>\n        Antineoplastic Agent, Vinca Alkaloid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957492\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Vincristine liposomal and conventional vincristine are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration. The liposomal vincristine dose is based on actual body surface area (BSA) and was not capped in studies (O&rsquo;Brien 2009; Rodriguez 2009; Silverman, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia (relapsed; Philadelphia chromosome-negative):</b> IV: 2.25 mg/m<sup>2</sup> once every 7 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957493\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957494\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, liposomal vincristine is minimally excreted by the kidney and like the conventional formulation, likely does not require dosage adjustment in renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957495\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment prior to treatment initiation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment (Child-Pugh class B): In a study in a limited number of melanoma patients with moderate (Child-Pugh class B) hepatic impairment secondary to liver metastases, C<sub>max </sub>and AUC were comparable to those in patients with normal hepatic function; patients with hepatic impairment received a dose of 1 mg/m<sup>2</sup> every 2 weeks versus 2 mg/m<sup>2</sup> in subjects with normal hepatic function (Bedikian 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity during treatment:</i> Reduce dose or interrupt treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957463\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Demyelinating conditions (including Charcot-Marie-Tooth syndrome):</i> Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Fatigue, severe:</i> Consider dose delay, reduction, or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hematologic toxicity:</i> Grade 3 or 4 neutropenia, thrombocytopenia, or anemia: Consider dose reduction or modification.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Peripheral neuropathy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 or persistent grade 2 toxicity: Interrupt therapy until recovery to grade 1 or 2, then reduce dose to 2 mg/m<sup>2</sup>. If grade 3 toxicity persists or if grade 4 toxicity occurs, discontinue liposomal vincristine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent grade 2 toxicity after first dose reduction to 2 mg/m<sup>2</sup>: Interrupt therapy for up to 7 days until recovery to grade 1, then reduce dose to 1.825 mg/m<sup>2</sup>. If neuropathy increases to grade 3 or 4, discontinue liposomal vincristine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent grade 2 toxicity after second dose reduction to 1.825 mg/m<sup>2</sup>: Interrupt therapy for up to 7 days until recovery to grade 1, then reduce dose to 1.5 mg/m<sup>2</sup>. If neuropathy increases to grade 3 or 4, discontinue liposomal vincristine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pre-existing neuropathy, severe: Assess treatment benefit versus risk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673722\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marqibo: 5 mg/31 mL (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957223\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957496\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>For IV administration only. FATAL IF GIVEN INTRATHECALLY.</b> Liposomal vincristine should <b>NOT</b> be delivered to the patient at the same time as any medications intended for central nervous system administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">IV: Infuse over 1 hour. Do not administer IV push or bolus; do not use with in-line filters. Do not administer with other medications. Infusion must be completed within 12 hours of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Conventional vincristine is a vesicant. Limited information is available regarding liposomal vincristine extravasation, but may cause inflammation if extravasated; avoid extravasation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132726\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14793790\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute lymphoblastic leukemia (relapsed): </b>Treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in adult patients in second or greater relapse or whose disease has progressed after two or more antileukemic therapies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957222\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VinCRIStine liposomal may be confused with vinCRIStine conventional</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">BEERS Criteria medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Conventional vincristine may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vincristine liposomal and conventional vincristine are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">For IV administration only. Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Liposomal vincristine should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep liposomal vincristine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Liposomal vincristine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14943496\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (41%), peripheral neuropathy (39%; grades 3/4: 17%), insomnia (32%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (57%), nausea (52%), diarrhea (37%), decreased appetite (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Febrile neutropenia (38%; grades 3/4: 31%), anemia (34%; grades 3/4: 17%), neutropenia (grades 3/4: 18%), thrombocytopenia (grades 3/4: 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (grades 3/4: 6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (43%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (grades 3/4: 6%), septic shock (grades 3/4: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (grades 3/4: 8%), mental status changes (grades 3/4: 4%), myasthenia (grades 3/4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (grades 3/4: 8%), intestinal obstruction (grades 3/4: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Staphylococcal bacteremia (grades 3/4: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (grades 3/4: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia (grades 3/4: 8%), respiratory distress (grades 3/4: 6%), respiratory failure (grades 3/4: 5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14958178\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to vincristine, liposomal vincristine, or any component of the formulation; patients with Charcot-Marie-Tooth syndrome or other demyelinating conditions; administration via the intrathecal route</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957225\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Grade 3 and greater neutropenia, anemia, and thrombocytopenia were observed in clinical trials. Monitor blood counts closely and adjust dose or withhold therapy if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: Constipation, ileus, bowel obstruction, and colonic pseudo-obstruction have occurred with liposomal vincristine. Patients should be initiated on a prophylactic bowel regimen including a stool softener, dietary fiber, and hydration; laxative treatments may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fatigue: Severe fatigue was noted in clinical trials; treatment delay, dosage adjustment or discontinuation may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity (including fatal cases) and increased AST have been reported. Monitor hepatic function tests; reduce dose or interrupt therapy if necessary. Use caution in patients with hepatic impairment; conventional vincristine undergoes extensive hepatic metabolism. Liposomal vincristine has not been studied in patients with severe hepatic impairment. In a study in a limited number of melanoma patients with moderate (Child-Pugh class B) hepatic impairment secondary to liver metastases, C<sub>max</sub> and AUC were comparable to those in patients with normal hepatic function; patients with hepatic impairment received a liposomal vincristine dose of 1 mg/m<sup>2 </sup>every 2 weeks versus 2 mg/m<sup>2</sup> in subjects with normal hepatic function (Bedikian 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Neuropathies (sensory and motor) are common and cumulative. Neuropathy symptoms may include paresthesia, hyper-/hypoesthesia, hyporeflexia or areflexia, neuralgia, jaw pain, cranial neuropathy, ileus, arthralgia, myalgia, muscle spasm, and/or weakness. Evaluate neurologic status of patients closely prior to liposomal vincristine administration; neurologic toxicity risk is greater when given to patients with preexisting neuromuscular conditions or when used concomitantly with other neurotoxic agents. Treatment delay, dosage adjustment, and/or discontinuation may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome may occur as a consequence of therapy; monitor closely for signs and symptoms and manage accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Avoid concomitant therapy with strong CYP3A4 or P-glycoprotein (P-gp) inducers or inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly patient population; conventional vincristine may cause or exacerbate hyponatremia or syndrome of inappropriate antidiuretic hormone secretion; monitor sodium closely with therapy initiation or dosage adjustments (Beers Criteria).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liposomal vs conventional formulation dosing: <b>[US Boxed Warning]: Vincristine liposomal and conventional vincristine are NOT interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration to avoid overdoses.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Avoid extravasation of liposomal vincristine (conventional vincristine is a vesicant). Only individuals experienced with vesicant administration should administer liposomal vincristine. Check for proper needle placement; if extravasation occurs, discontinue liposomal vincristine infusion immediately and institute appropriate extravasation management procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Not for intrathecal administration: <b>[US Boxed Warning]: For IV administration only. Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. </b>Liposomal vincristine should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep liposomal vincristine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Liposomal vincristine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14975281\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14975279\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=86240&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of VinCRIStine (Liposomal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of VinCRIStine (Liposomal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May increase the serum concentration of VinCRIStine (Liposomal).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of VinCRIStine (Liposomal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of VinCRIStine (Liposomal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of VinCRIStine (Liposomal).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of VinCRIStine (Liposomal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teniposide: May enhance the neurotoxic effect of VinCRIStine (Liposomal).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14958175\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14958176\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events (fetal malformations, decreased fetal weight, and fetal loss) were observed in animal reproduction studies at doses less than the recommended human dose. Based on the mechanism of action, adverse fetal events would be expected to occur with use in pregnant women. Women of reproductive potential should avoid becoming pregnant during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14958177\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if liposomal vincristine is present in breast milk. Due to the potential for adverse reactions in the breastfed infant, the decision to discontinue breastfeeding or to discontinue liposomal vincristine should take into account the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957528\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets; hepatic function; signs/symptoms of peripheral neuropathy or other neurologic toxicities; sodium (in elderly patients; conventional vincristine may cause or exacerbate hyponatremia or syndrome of inappropriate antidiuretic hormone secretion); signs/symptoms of tumor lysis syndrome; symptoms of constipation; monitor infusion site for extravasation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957368\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The vincristine liposomal formulation increases the half-life, allowing for enhanced cytotoxic activity in tumor cells. The liposomal formulation of vincristine consists of vincristine encapsulated in sphingosomes, which are composed of sphingomyelin and cholesterol (Bedikian 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14957384\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 2.7 L (Bedikian 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 45 hours (urinary half-life); dependent on rate of vincristine release from sphingosome (Bedikian 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (69%); urine (&lt;8%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613355\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Marqibo Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/31 mL (1): $15,889.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2012 Beers Criteria Update Expert Panel, &quot;American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,&quot; <i>J Am Geriatr Soc</i>, 2012, 60(4):616-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-vincristine-drug-information/abstract-text/22376048/pubmed\" target=\"_blank\" id=\"22376048\">22376048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bedikian AY, Silverman JA, Papadopoulos NE, et al, &ldquo;Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function,&rdquo; <i>J Clin Pharmacol</i>, 2011, 51(8):1205-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-vincristine-drug-information/abstract-text/20978276/pubmed\" target=\"_blank\" id=\"20978276\">20978276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bedikian AY, Vardeleon A, Smith T, et al, &ldquo;Pharmacokinetics and Urinary Excretion of Vincristine Sulfate Liposomes Injection in Metastatic Melanoma Patients,&rdquo; <i>J Clin Pharmacol</i>, 2006, 46(7):727-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-vincristine-drug-information/abstract-text/16809798/pubmed\" target=\"_blank\" id=\"16809798\">16809798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boman NL, Tron VA, Bally MB, et al. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. <i>Cancer Chemother Pharmacol</i>. 1996;37(4):351-355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-vincristine-drug-information/abstract-text/8548881/pubmed\" target=\"_blank\" id=\"8548881\">8548881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Damon LE, Goldberg SL, Heffner LT, et al, &ldquo;Neurological Toxicity Profile of Weekly Vincristine Sulfate Liposomes Injection (Marqibo&reg;) 2.25 mg/m<sup>2</sup> Compared to Historical Standard Vincristine Sulfate 1.4 mg/m<sup>2</sup>, 2 mg, and 4 mg Administered Less Frequently,&rdquo; <i>Blood</i>, 2011, 118(21):4247 [abstract 4247 from 2011 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heffner L, &ldquo;A New Formulation of Vincristine for Acute Lymphoblastic Leukemia,&rdquo; <i>Clin Adv Hematol Oncol</i>, 2011, 9(4):314-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-vincristine-drug-information/abstract-text/21558991/pubmed\" target=\"_blank\" id=\"21558991\">21558991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marqibo (vincristine liposomal) [prescribing information]. Irvine, CA: Talon Therapeutics Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'brien S, Schiller G, Damon LE, et al, &ldquo;Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo&reg;) in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-Leukemia Treatment Lines,&rdquo; <i>Blood</i>, 2009, 114(22):3088 [abstract 3088 from 2009 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'brien S, Thomas DA, Heffner LT, et al, &ldquo;Marqibo&reg; (Vincristine Sulfate Liposomes Injection; VSLI) in the Treatment of Adult Patients With Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies,&rdquo; <i>Blood</i>, 2010, 116(21):2143 [abstract 2143 from 2010 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez MA, Pytlik R, Kozak T, et al; Marqibo Investigators. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. <i>Cancer</i>. 2009;115(15):3475-3482. doi:10.1002/cncr.24359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-vincristine-drug-information/abstract-text/19536896/pubmed\" target=\"_blank\" id=\"19536896\">19536896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schiller GJ, Lister J, Heffner LT, et al, &ldquo;Vincristine Sulfate Liposomes Injection (Marqibo&reg;) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults With Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia,&rdquo; <i>Blood</i>, 2011, 118(21):4235 [abstract 4235 from 2011 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverman JA, Aulitzky WE, Lister J, et al, &ldquo;Marqibo&reg; (Vincristine Sulfate Liposomes Injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL),&rdquo; <i>Blood</i>, 2010, 116(21):2142 [abstract 2142 from 2010 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas DA, Sarris AH, Cortes J, et al, &ldquo;Phase II Study of Sphingosomal Vincristine in Patients With Recurrent or Refractory Adult Acute Lymphocytic Leukemia,&rdquo; <i>Cancer</i>, 2006, 106(1):120-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-vincristine-drug-information/abstract-text/16331634/pubmed\" target=\"_blank\" id=\"16331634\">16331634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 86240 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F14793786\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24673721\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14793788\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14957492\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14957493\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14957494\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14957495\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F14957463\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24673722\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F14957223\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14957496\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132726\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14793790\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14957222\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14943496\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14958178\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14957225\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14975281\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14975279\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F14958175\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14958176\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14958177\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14957528\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14957368\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F14957384\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23613355\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/86240|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=liposomal-vincristine-patient-drug-information\" class=\"drug drug_patient\">Liposomal vincristine: Patient drug information</a></li></ul></div></div>","javascript":null}